AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37522226
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg plus ezetimibe 10 mg
Trial: 32664145
Drug: Bushen Yisui
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bushen Yisui and Ziyin Jiangzhuo (BYZJ) granules administered twice daily for 4 weeks
Trial: 32664145
Drug: Placebo (simulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (simulated granules) administered twice daily for 4 weeks
Trial: 32055822
Drug: PF‐06412562 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐06412562 (3 mg twice daily)
Trial: 32055822
Drug: PF‐06412562 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐06412562 (15 mg twice daily)
Trial: 35197189
Drug: No standardized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No standardized delirium prevention and treatment measures (control)
Trial: 34684351
Drug: Ginseng Extract
RxNorm normalized name: ginseng extract
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginseng Extract 3 g
Trial: 36867173
Drug: Lithium augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium augmentation
Trial: 32957571
Drug: Quercetin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin (1000 mg/day)
Trial: 35276922
Drug: High-quality, optimal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-quality, optimal protein diet (1.9 g·kg−1·d−1)
Trial: 35276922
Drug: Adequate protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adequate protein diet (1.2 g·kg−1·d−1)
Trial: 34330599
Drug: Glucantime® +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucantime® + Oral Tamoxifen
Trial: 33156688
Drug: Breast milk
RxNorm normalized name: BREAST MILK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast milk for oral care
Trial: 35322777
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate solution for oral care
Trial: 32483675
Drug: 0.25% Timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% Timolol Gel
Trial: 32483675
Drug: 0.5% Timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% Timolol Gel
Trial: 32483675
Drug: Carbonic Anhydrase
RxNorm normalized name: Carbonic anhydrase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbonic Anhydrase Inhibitors (CAI)
Trial: 36273314
Drug: 300 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 μg GCSF administered intrauterine with hCG injection
Trial: 36273314
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline administered intrauterine with hCG injection
Trial: 39076624
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (TIVA)
Trial: 36368750
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g
Trial: 36368750
Drug: Ceftriaxone 500
RxNorm normalized name: ceftriaxone 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 500 mg plus 2 g azithromycin
Trial: 32620345
Drug: Aurai water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aurai water propelled, heating Eye Massager (AEM) used twice a day for 2 weeks
Trial: 36237580
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese and Western medicine
Trial: 38580946
Drug: Medication
RxNorm normalized name: Acne Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication
Trial: 35486196
Drug: Discontinuous Treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuous Treatment (DT)
Trial: 33082194
Drug: Fingolimod 0.5
RxNorm normalized name: fingolimod 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod 0.5 mg once daily
Trial: 35272176
Drug: Vildagliptin 100
RxNorm normalized name: vildagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin 100 mg modified release once daily (QD)
Trial: 35272176
Drug: Vildagliptin 50
RxNorm normalized name: vildagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin 50 mg immediate release twice daily (BID)
Trial: 33320381
Drug: Standard-dose ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose ticagrelor (SD group, 90 mg twice daily)
Trial: 33047732
Drug: S-P-BG group
RxNorm normalized name: P & S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-P-BG group (5% STMP, 5% PAA, 0.5 g/L BG)
Trial: 33047732
Drug: BG group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BG group (0.5 g/L BG)
Trial: 32459375
Drug: Full-dose TKIs
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose TKIs
Trial: 36302195
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal oxygen therapy
Trial: 32100497
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at acupoints (Tiantu, Danzhong, Zhongwan, Zusanli, Taichong, Neiguan) plus esomeprazole (20 mg, twice a day) and mosapride (5 mg, three times a day) for 14 days.
Trial: 32100497
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with esomeprazole (20 mg, twice a day) and mosapride (5 mg, three times a day) for 14 days.
Trial: 38985162
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide 3 mg
Trial: 38985162
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide 7 mg
Trial: 38985162
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide 14 mg
Trial: 35983530
Drug: Injectable salvianolic
RxNorm normalized name: Salvianolic acid A
DrugBank: Salvianolic acid A (DB15246)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable salvianolic acid treatment
Trial: 35081366
Drug: Fascial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fascial therapy intervention (3 weeks, 45-minute weekly sessions)
Trial: 36018547
Drug: Camel milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camel milk (200 milliliters daily for 2 months)
Trial: 33941940
Drug: Single preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single preoperative oral dose of 500mg amoxicillin
Trial: 33941940
Drug: Single preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single preoperative oral dose of 400mg metronidazole
Trial: 33941940
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (500mg of Amoxicillin BD, 400mg of metronidazole and painkillers postoperatively)
Trial: 33981141
Drug: Rengalin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rengalin (2 tablets 2 times daily for 4 weeks)
Trial: 33981141
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 tablets 2 times daily for 4 weeks)
Trial: 37950338
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg
Trial: 39593191
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg
Trial: 34185197
Drug: Tyrosine kinase
RxNorm normalized name: Protein-tyrosine kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitors (TKI)
Trial: 36258248
Drug: Baclofen (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (10, 30, 60, or 90 mg)
Trial: 34582477
Drug: Hydroxychloroquine 400
RxNorm normalized name: hydroxychloroquine 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 400 mg/day for 10 days
Trial: 34142111
Drug: CT-P17 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-P17 (100 mg/ml) continued every 2 weeks (Q2W)
Trial: 34142111
Drug: CT-P17 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-P17 (100 mg/ml) switched from reference adalimumab
Trial: 32613664
Drug: ERL monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERL monotherapy (n = 27)
Trial: 36386549
Drug: Risk-based stratified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk-based stratified care using Keele's STarT MSK Tool and risk-matched treatments
Trial: 36386549
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (advice, education, medication, referrals)
Trial: 33772710
Drug: Control (no-treatment)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (no-treatment)
Trial: 33566065
Drug: Psilocybin-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin-assisted therapy
Trial: 32541299
Drug: Conjugated estrogen
RxNorm normalized name: Conjugated estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated estrogen vaginal cream (applied for at least 5 weeks preoperatively and continued twice-weekly through 12 months postoperatively)
Trial: 32716320
Drug: Pimavanserin 34
RxNorm normalized name: pimavanserin 34 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimavanserin 34 mg once daily
Trial: 36342475
Drug: Aspirin 100mg
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 100mg once daily
Trial: 33724614
Drug: Oxygen–ozone therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen–ozone therapy (O2–O3)
Trial: 33569757
Drug: One implant
RxNorm normalized name: Testosterone Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One implant in the midline of the mandibular symphysis (GA group)
Trial: 33569757
Drug: Two implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two implants in the lower canine region (GB group)
Trial: 33569757
Drug: Two implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two implants (GB group)
Trial: 35314068
Drug: Implant Studio
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implant Studio
Trial: 38387597
Drug: 38% silver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 38% silver diamine fluoride (SDF) treatment
Trial: 34511330
Drug: CLEC4C in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLEC4C in combination with clinical covariates from the multivariable model
Trial: 36108657
Drug: Combined nivolumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined nivolumab (240 mg IV every 2 weeks) and ipilimumab (1 mg/kg IV every 6 weeks)
Trial: 36108657
Drug: Combined nivolumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined nivolumab (240 mg IV every 2 weeks) and ipilimumab (1 mg/kg IV every 6 weeks) plus SBRT (24 Gy in three fractions at week 2)
Trial: 38900037
Drug: Treatment-related adverse
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-related adverse events
Trial: 34671996
Drug: Namodenoson 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Namodenoson 12.5 mg b.d.
Trial: 35526605
Drug: Pyridostigmine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (60 mg oral)
Trial: 33541836
Drug: Walnut smoothie
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut smoothie (48 g walnuts)
Trial: 616840383
Drug: He-Mu point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: He-Mu point combination group (puncturing at ST36 and CV12)
Trial: 33630475
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC) chemotherapy and chemoradiation (N = 158)
Trial: 33630475
Drug: HAPa immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAPa immunotherapy combined with SOC chemotherapy and chemoradiation (N = 145)
Trial: 34424307
Drug: High-dose HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose HBV vaccination (3 doses of 40 μg recombinant hepatitis B vaccine at 0, 1, and 2 months)
Trial: 34424307
Drug: Standard-dose HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose HBV vaccination (3 doses of 20 μg each at 0, 1, and 2 months)
Trial: 34424307
Drug: High-dose HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose HBV vaccination
Trial: 34424307
Drug: Standard-dose HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose HBV vaccination
Trial: 32984946
Drug: Polaprezinc (PZ)
RxNorm normalized name: polaprezinc
DrugBank: Polaprezinc (DB09221)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polaprezinc (PZ) lozenge treatment started before chemotherapy
Trial: 32984946
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (PZ lozenges initiated after onset of Grade 2 oral mucositis)
Trial: 32171499
Drug: ESP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESP block with 20 mL of 0.5% ropivacaine bilaterally at T8 level
Trial: 32171499
Drug: Epidural block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural block with 20 mL of 0.5% ropivacaine and 1 mg of morphine at T8-T9 space
Trial: 36331502
Drug: Conventional rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional rehabilitation therapy (control group)
Trial: 33028335
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of three BCTs (action planning, coping planning, self-monitoring)
Trial: 33028335
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of action planning and self-monitoring
Trial: 34210360
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg CBDV
Trial: 32485422
Drug: Active Treatment
RxNorm normalized name: Active
DrugBank: Octisalate (DB11062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active Treatment A (intermittent vibrational cutaneous stimulation)
Trial: 32485422
Drug: Passive Treatment
RxNorm normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive Treatment B (no active stimulation)
Trial: 32485422
Drug: Active Treatment
RxNorm normalized name: Active
DrugBank: Octisalate (DB11062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active Treatment A
Trial: 36149628
Drug: Combined intracervical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intracervical foley’s catheter plus intravenous oxytocin infusion
Trial: 32764090
Drug: Pharmacogenomic-guided dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenomic-guided dual antiplatelet therapy (DAPT) with ticagrelor for high-risk patients
Trial: 35765086
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia with cryotherapy (TC)
Trial: 35765086
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia alone (T)
Trial: 34990002
Drug: Baricitinib 2-mg
RxNorm normalized name: baricitinib 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 2-mg
Trial: 37634517
Drug: Deferred treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred treatment
Trial: 37769311
Drug: Elagolix 150
RxNorm normalized name: elagolix 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elagolix 150 mg once daily
Trial: 34451976
Drug: MVA-NP+M1 vaccine
RxNorm normalized name: Ceramide Np
DrugBank: Ceramide NP (DB14111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA-NP+M1 vaccine combined with annual influenza vaccine
Trial: 33688834
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug
Trial: 36438071
Drug: Silymarin (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (140 mg every 8 hours for 4 weeks)
Trial: 36438071
Drug: Placebo (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (same tablet shape, same dosage as silymarin)
Trial: 39464932
Drug: Insulin degludec/insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin degludec/insulin aspart (IDegAsp)
Trial: 33773170
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus Chinese medicine
Trial: 35262315
Drug: Social learning
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social learning group (SoLG) observing positive treatment outcomes in a sham patient
Trial: 32061002
Drug: Low radiation
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low radiation dose contrast‐enhanced mammography (L‐CEM)
Trial: 36348309
Drug: Supervised group-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised group-based combined exercise therapy and education (SET)
Trial: 33315489
Drug: Integral prasugrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integral prasugrel tablets (60 mg loading dose)
Trial: 33315489
Drug: Crushed prasugrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed prasugrel tablets (60 mg loading dose)
Trial: 36054089
Drug: Melatonin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (5 mg daily)
Trial: 32770222
Drug: Graphic warning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Graphic warning labels with 'US Food and Drug Administration' sponsorship
Trial: 39664835
Drug: Atraumatic restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic restorative treatment (ART)
Trial: 39664835
Drug: Ultraconservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultraconservative treatment (UCT)
Trial: 35321886
Drug: Sodium lactate
RxNorm normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium lactate infusion
Trial: 33210285
Drug: Control (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (20 cc normal saline)
Trial: 33121714
Drug: Baseline NT-proBNP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline NT-proBNP ≥125 pg/ml
Trial: 36898948
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy
Trial: 33412344
Drug: Nonnutritive sucking
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonnutritive sucking (NNS) twice a day for 10 days during two consecutive weeks
Trial: 33412344
Drug: Combined program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined program of NNS (15 min) and swallowing exercise (SE) (15 min) daily for 10 days during two consecutive weeks
Trial: 33848307
Drug: Pure essential
RxNorm normalized name: Nature's Truth Pure Essential Oil Rosemary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pure essential oil therapy (sandalwood)
Trial: 33848307
Drug: Blended essential
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended essential oil therapy (sandalwood-lavender)
Trial: 34661770
Drug: Buccal pad
RxNorm normalized name: Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal pad of fat sandwiched with a nasolabial flap (Group I)
Trial: 34661770
Drug: Buccal pad
RxNorm normalized name: Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal pad of fat combined with a collagen graft (Group II)
Trial: 33065181
Drug: MRI-based IGBT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI-based IGBT with ureteral dose D0.1cm3 ≥77 Gy
Trial: 33065181
Drug: MRI-based IGBT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI-based IGBT with ureteral dose D0.1cm3 <77 Gy
Trial: 36856877
Drug: PGE1 treatment
RxNorm normalized name: PGE1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PGE1 treatment
Trial: 615919275
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg RBZ
Trial: 35587540
Drug: Buccal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal misoprostol 25 μg followed by 50 μg every 4 hours
Trial: 35278780
Drug: Internet-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive-behavioral grief therapy (ICBGT)
Trial: 34621545
Drug: Polyethylene cover
RxNorm normalized name: Canker Cover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene cover plus Lubratex eye ointment
Trial: 35231887
Drug: Dapsone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone (100 mg daily)
Trial: 34392146
Drug: 80 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/day anthocyanins for 12 weeks